Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

6 de noviembre de 2026 actualizado por: Novartis Pharmaceuticals

VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome, Followed by an Open-Label Extension Period

The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This is a randomized, double-blind, placebo-controlled study with a 52-week duration evaluating the efficacy and safety of arumakimig in participants with VEXAS who are receiving glucocorticoids. Participants will be randomized 1:1 to either arumakimig or placebo.

Following the double-blind period, participants may have the option to enter a 2-year (104-week) open-label extension (OLE) period, continuing until Week 156.

A 16-week safety follow-up period must be completed after the OLE (up to Week 172) or after the double-blind period (up to Week 68).

Tipo de estudio

Intervencionista

Inscripción (Estimado)

120

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Novartis Pharmaceuticals
  • Número de teléfono: +41613241111

Ubicaciones de estudio

      • Fukushima, Japón, 9601295
        • Reclutamiento
        • Novartis Investigative Site
      • Niigata, Japón, 9518520
        • Reclutamiento
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japón, 2360004
        • Reclutamiento
        • Novartis Investigative Site
    • Osaka
      • Suita, Osaka, Japón, 5650871
        • Reclutamiento
        • Novartis Investigative Site
    • Tokyo
      • Hachiōji, Tokyo, Japón, 1930998
        • Reclutamiento
        • Novartis Investigative Site
      • Shinjuku-ku, Tokyo, Japón, 1608582
        • Reclutamiento
        • Novartis Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Male and female participants aged ≥18 years at screening.
  • Somatic mutation in UBA1 gene known to be associated with VEXAS.
  • Participants must have at least two manifestations of VEXAS at screening or in the past 6 months.
  • Participants must be able to start treatment for Pneumocystis jiroveci pneumonia (PJP) during the study if indicated according to the local guidelines.
  • Ability to communicate well with the Investigator, understand and agree to comply with the requirements of the study.

Exclusion Criteria:

  • Participants meeting any of the following criteria are not eligible for this study:
  • Positive serology for hepatitis B surface antigen (HBsAg) excludes the participant.

HBsAg negative participants who are hepatitis B core antibody (HBcAb) positive are also excluded unless protocol-defined criteria are met.

  • Participants with a positive HCV antibody test should have HCV ribonucleic acid (RNA) levels measured. Participants with positive (detectable) HCV RNA must be excluded. Chronic hepatitis C patients who have completed HCV anti-viral treatment must be HCV-RNA negative at least 12 weeks after treatment before randomization to be eligible.
  • Active viral, bacterial, or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infections.
  • Known or suspected Human Immunodeficiency Virus (HIV) infection. Should it be required by local regulations and/or considered appropriate by the Investigator, an HIV test can be performed locally to confirm eligibility.
  • Live vaccinations within a certain period prior to arumakimig treatment. Live vaccines are prohibited during the trial and up to a certain period following the last dose of arumakimig.
  • History of malignancy of any organ system, including post-transplant lymphoproliferative disorder (except for skin Bowen's disease, completely treated and resolved, localized squamous or basal cell carcinoma of the skin or actinic keratosis that have been treated with no evidence of recurrence in the past 12 weeks, in situ cervical cancer or non-invasive malignant colon polyps that have been removed), treated or untreated, within a protocol-defined period, regardless of whether there is evidence of local recurrence or metastases.
  • History of or current hepatic disease (moderate to severe Hepatic Impairment as per Child-Pugh classification), including but not limited to, acute or chronic hepatitis (for Hepatitis B or C), cirrhosis or hepatic failure.
  • Participants of child-bearing potential who do not agree to comply with required contraceptive use as outlined in the protocol.

Other protocol-defined inclusion/exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arumakimig

Arumakimig from Day 1 to Week 52 during the double-blind period. Eligible participants may then continue into an open-label extension and receive arumakimig through Week 156.

Arumakimig Injection

Otros nombres:
  • MAS825

Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement.

Comparador de placebos: Placebo

Placebo from Day 1 to Week 52 during the double-blind period. Eligible participants may then continue into an open-label extension and receive arumakimig through Week 156.

Arumakimig Injection

Otros nombres:
  • MAS825

Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement.

Placebo Injection

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants achieving improvement of key VEXAS manifestations and oral glucocorticoid (GC) reduction at Week 52
Periodo de tiempo: From baseline up to Week 52

Response is defined as meeting both criteria:

A) Clinical domain: In participants with clinical disease activity in any domain at baseline, complete resolution of clinical manifestations related to active disease in at least one affected domain. In participants with no clinical disease activity in any domain at baseline, continued absence of clinical manifestations in all domains at Week 52.

AND B) Protocol-defined glucocorticoid reduction through 52 weeks.

From baseline up to Week 52

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants achieving Overall Clinical Response (OCR) at Week 52
Periodo de tiempo: From baseline up to Week 52

Achieving OCR at Week 52 is defined as meeting all the following criteria:

  • Absence of active inflammatory manifestations of VEXAS
  • Protocol-defined reduction in oral glucocorticoid.
  • Protocol-defined reduction in C reactive protein.
From baseline up to Week 52
Number of participants achieving resolution of VEXAS manifestations
Periodo de tiempo: From baseline up to Week 52

In participants with clinical disease activity in any domain at baseline, achieving complete resolution of clinical manifestations.

From baseline up to Week 52
Number of participants with oral glucocorticoid reduction
Periodo de tiempo: From baseline up to Week 52

Number of participants achieving protocol-defined glucocorticoid dose reduction through 52 weeks.

From baseline up to Week 52
Total number of flare-free days over 52 weeks
Periodo de tiempo: Up to 52 weeks

Total cumulative number of days over 52 weeks meeting the protocol-defined criteria for a flare-free day.

Up to 52 weeks
Number of participants achieving Hematologic Improvement - Erythroid (HI-E) during the double-blind treatment period
Periodo de tiempo: From baseline up to Week 52

Hematologic Improvement - Erythroid (HI-E) during the double-blind 52-week treatment period among participants with baseline hemoglobin within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria.

From baseline up to Week 52
Number of participants achieving Hematologic Improvement - Platelets (HI-P) during the double-blind treatment period
Periodo de tiempo: From baseline up to Week 52

Hematologic Improvement - Platelets (HI-P) during the double-blind 52-week treatment period among participants with baseline platelets within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria.

From baseline up to Week 52
Number of participants without worsening disease according to a participant-reported questionnaire
Periodo de tiempo: From baseline up to Week 52

Participants without protocol-defined worsening of disease according to a participant-reported questionnaire.

From baseline up to Week 52
Time to death during the double-blind treatment period
Periodo de tiempo: Up to 52 weeks

Assessment of mortality through Week 52 in each treatment arm.

Up to 52 weeks
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Periodo de tiempo: Up to 172 weeks

Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms and laboratory values qualifying and reported as AEs.

Up to 172 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

30 de octubre de 2026

Finalización primaria (Estimado)

26 de diciembre de 2028

Finalización del estudio (Estimado)

15 de abril de 2031

Fechas de registro del estudio

Enviado por primera vez

31 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

31 de julio de 2026

Publicado por primera vez (Actual)

6 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CMAS825G12203
  • 2026-527354-39 (Identificador de registro: EU CTIS)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .